BiofronteraBFRI
Market Cap: $6.15M
About: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Employees: 85
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
9% more funds holding
Funds holding: 11 [Q1] → 12 (+1) [Q2]
1.63% more ownership
Funds ownership: 21.33% [Q1] → 22.97% (+1.63%) [Q2]
37% less capital invested
Capital invested by funds: $1.67M [Q1] → $1.05M (-$616K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Benchmark Bruce Jackson 27% 1-year accuracy 13 / 48 met price target | 531%upside $7 | Buy Reiterated | 16 Aug 2024 |
Financial journalist opinion
Based on 3 articles about BFRI published over the past 30 days